GEMOX方案一线治疗晚期转移性胆道系统肿瘤的临床观察  

Clinical observation on gemcitabine combined with oxaliplatin as the first-line regimen for advanced biliary tract carcinoma

作　　者：李嵘[1] 秦叔逵[1] 刘秀峰[1] 华海清[1] 王琳[1] 

机构地区：[1]解放军八一医院全军肿瘤中心内科,南京210002

出　　处：《临床肿瘤学杂志》2012年第11期1020-1023,共4页Chinese Clinical Oncology

摘　　要：目的探讨吉西他滨联合奥沙利铂(GEMOX)方案一线治疗晚期转移性胆道系统肿瘤的疗效及安全性。方法收集2005年7月至2012年4月共49例接受GEMOX方案一线治疗的晚期胆道系统肿瘤患者,具体方案为:吉西他滨1000mg/m2静滴,d1、d8;奥沙利铂100mg/m2静滴,d2,21天为1周期,2个周期后评价疗效。结果 49例患者共接受了239个周期化疗,平均4.88个周期(2～10个周期)。49例患者均可评价疗效和毒副反应,获CR 2例(4.1%),PR 8例(16.3%),SD26例(53.1%),PD 13例(26.5%),总有效率(RR)为20.4%,疾病控制率(DCR)为73.5%。中位疾病进展时间(mTTP)为6.0个月,中位生存时间(mOS)为11.0个月。主要毒副反应为白细胞减少、血小板减少、恶心呕吐和肝功能损害,均以1～2级为主。结论 GEMOX方案治疗晚期转移性胆道系统肿瘤疗效较好,毒副反应可耐受,值得临床进一步应用。Objective To observe the efficacy and safety of gemcitabine combined with oxaliplatin（GEMOX） as the first-line regimen for advanced biliary tract carcinoma. Methods From July 2005 to April 2012,49 patients with biliary tract carcinoma were treated with GEMOX regimen as the first-line regimen. GEMOX regimen was taken as follow： gemeitabine 1000mg/m2 iv d1 , d8 ; ox- aliplatin 100mg/m2 iv d2. Twenty-one days was a cycle. The efficacy was evaluated after 2 cycles. Results All the patients received 239 cycles in total with the mean eylees was 4. 88 ranged from 2 to 10, and the efficacy and side effects could be evaluated in all. In the49 patients, 2（4.1%） got CR,8（16.3%） PR, 26（53.1%） SD and 13（26.5%） PD. The overall response rate（RR） was 20.4% and disease control rate was 73.5%. The median time to pregress was 6. 0 months and the median overall survival was 11.0 months. The main side effects were leukopenia, thromboeytopenia, vomiting/nausea and liver function impairment. They were mainly in grade 1-2. Conclusion GEMOX regimen is effective and tolerable in the treatment of advanced biliary tract carcinoma, and is worth of further clinical application.

关 键 词：胆道系统肿瘤 吉西他滨 奥沙利铂 联合化疗 

分 类 号：R735.8[医药卫生—肿瘤]